Rizafilm
Product Images NDC 35781-0600

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Rizafilm (NDC 35781-0600). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Gensco Laboratories Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pouch Of 1 Film (Pouch)

RIZAFILM oral film 10 mg packaging label with dosage and usage instructions. The front shows the product name, strength, dosage form, quantity of 1 film, and labeler Gensco Pharma. The back provides recommended dosage and storage, usage directions to place film on tongue, and manufacturer information including IntelGenx Corp Canada. Barcode and NDC 35781-0600-1 are visible.*

FDA Label Image

Carton Of 18 Films (Carton 18)

RizaFilm 10 mg oral film packaging label for rizatriptan benzoate by Gensco Laboratories LLC. The label indicates 18 films per package with the proprietary name RizaFilm and generic name rizatriptan prominently displayed. The label includes dosage strength and identifies the product as Rx only.*

FDA Label Image

Figure1 (Fig1)

A line graph comparing the estimated probability of response over time between Rizatriptan Benzoate 10 mg and placebo. The x-axis represents time (units not specified), while the y-axis shows the estimated probability of response ranging from 0% to 100%. The Rizatriptan Benzoate 10 mg line shows a higher probability of response compared to placebo throughout the observed period.*

FDA Label Image

Figure2 (Fig2)

A line graph comparing the estimated probability of remediation or rescue over 24 hours post-dose between placebo and rizatriptan benzoate 10 mg. The x-axis shows hours post-dose (0 to 24), and the y-axis shows the probability percentage (0% to 100%). Two lines represent placebo and rizatriptan benzoate 10 mg, illustrating differences in response over time.*

FDA Label Image

Figure3 (Fig3)

A line graph showing the estimated probability of response over time (hours post-dose) comparing Rizatriptan Benzoate 10 mg film to placebo. The vertical axis represents the probability of response in percentage, ranging from 0% to 100%. The horizontal axis shows time from 0 to 2 hours post-dose. Rizatriptan Benzoate 10 mg demonstrates a higher probability of response compared to placebo at all measured time points.*

FDA Label Image

Figure4 (Fig4)

A line graph showing the estimated probability of remediation or rescue over 24 hours post-dose. The x-axis represents hours post-dose from 0 to 24, and the y-axis shows probability percentages from 0% to 100%. Two curves compare placebo and Rizatriptan Benzoate 10 mg, with placebo showing a higher probability throughout the time period.*

FDA Label Image

Figure5 (Fig5)

A line graph comparing the percent effect over time (hours post stage 2 dose) between rizatriptan benzoate and placebo. The x-axis shows hours (0.5 to 2.0), and the y-axis shows percent with 95% confidence intervals. Rizatriptan benzoate is represented by a solid line with filled circles; placebo is a dashed line with open circles, indicating higher percent values for rizatriptan benzoate at later time points.*

FDA Label Image

Structure (Structure)

Chemical structure of rizatriptan benzoate, showing its molecular components and arrangement as found in the active ingredient of RIZAFILM oral film.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.